Bisphosphonate therapy in rheumatoid arthritis

被引:47
作者
Breuil, Veronique [1 ]
Euller-Ziegler, Liana [1 ]
机构
[1] Hop Archet, Dept Rheumatol, F-06202 Nice 3, France
关键词
rheumatoid arthritis; bisphosphonate; bone loss; focal bone damage; osteoclast;
D O I
10.1016/j.jbspin.2005.10.019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Focal bone damage and generalized bone loss are features of rheumatoid arthritis (RA). The introduction of TNF alpha antagonists has radically improved the management of RA by providing a means of slowing or preventing the occurrence of focal bone damage. However, some patients with severe RA have contraindications to TNF alpha antagonist therapy and others either fail to respond or fail to tolerate TNF alpha antagonists. In addition, whether TNF alpha antagonists effectively combat generalized bone loss remains unknown. Bisphosphonates can prevent generalized bone loss. Their main target is the osteoclast, which has been identified as the culprit in focal bone damage caused by inflammatory diseases. As a result, the potential effects of bisphosphonates on focal bone damage related to RA are generating strong interest. Although results from the few studies in humans have been disappointing, new insights into the mechanisms of action of amino-bisphosphonates and recent data obtained in animals, most notably with new-generation bisphosphonates, have rekindled the hope that bisphosphonates may be beneficial in RA. We review herein the main studies of the effects of bisphosphonate therapy on focal bone damage and generalized bone loss in patients with RA. (c) 2006 Elsevier SAS. All rights reserved.
引用
收藏
页码:349 / 354
页数:6
相关论文
共 51 条
[1]  
AFSSAPS, 2003, TRAITEMENT MEDICAMEN
[2]  
Barrera P, 2000, ARTHRITIS RHEUM-US, V43, P1951, DOI 10.1002/1529-0131(200009)43:9<1951::AID-ANR5>3.0.CO
[3]  
2-K
[4]  
Cantatore FP, 1999, J RHEUMATOL, V26, P2318
[5]  
COHENSOLAL M, 2005, REV RHUM, V72, P366
[6]  
Cremers SCLM, 2004, J RHEUMATOL, V31, P1732
[7]   Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients [J].
Eastell, R ;
Devogelaer, JP ;
Peel, NFA ;
Chines, AA ;
Bax, DE ;
Sacco-Gibson, N ;
de Deuxchaisnes, CN ;
Russell, RGG .
OSTEOPOROSIS INTERNATIONAL, 2000, 11 (04) :331-337
[8]   Increased bone mass with pamidronate treatment in rheumatoid arthritis - Results of a three-year randomized, double-blind trial [J].
Eggelmeijer, F ;
Papapoulos, SE ;
vanPaassen, HC ;
Dijkmans, BAC ;
Valkema, R ;
Westedt, ML ;
Landman, JO ;
Pauwels, EKJ ;
Breedveld, FC .
ARTHRITIS AND RHEUMATISM, 1996, 39 (03) :396-402
[9]  
EGGELMEIJER F, 1994, J RHEUMATOL, V21, P2016
[10]  
FORSBLAD DH, 2003, ANN RHEUM DIS, V62, P617